-
1
المؤلفون: Klaas van der Linde, Michelle S G Sikkens, Yvonne J B van Megen, M. W. M. D. Lutgens, Joanne P J Bloemsaat-Minekus, Corinne M Stoop, Andrea Van Der Meulen, Halil Akol, Marieke Pierik, Johan Kuijvenhoven, Ids J. Klompmaker, Gerard Dijkstra
المساهمون: Interne Geneeskunde, MUMC+: MA Maag Darm Lever (9), RS: NUTRIM - R2 - Liver and digestive health
المصدر: Crohn's & Colitis 360, 4(3):001. Oxford University Press
Crohn's & Colitis 360, 4(3). OXFORD UNIV PRESSمصطلحات موضوعية: medicine.medical_specialty, business.industry, Gastroenterology, Biosimilar, EFFICACY, medicine.disease, THERAPY, Inflammatory bowel disease, CROHNS-DISEASE, Infliximab, quality of life, Quality of life, inflammatory bowel disease, Internal medicine, END-POINTS, medicine, biosimilar, INHIBITORS, infliximab, business, medicine.drug
وصف الملف: application/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfe906b4eebf52832318eaa05e6cf380
https://doi.org/10.1093/crocol/otab001 -
2
المؤلفون: Anne S. Strik, Yvonne J B van Megen, Michael T. Nurmohamed, Wim van de Vrie, Theo Rispens, Joanne P J Bloemsaat-Minekus, Peter Bossuyt, Alexander Bodelier, Geert R. D'Haens
المساهمون: Gastroenterology and hepatology, Rheumatology, ACS - Atherosclerosis & ischemic syndromes, AII - Inflammatory diseases, AGEM - Digestive immunity, Gastroenterology and Hepatology, Graduate School, Landsteiner Laboratory
المصدر: SECURE study group 2018, ' Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE) : an open-label, multicentre, phase 4 non-inferiority trial ', The Lancet Gastroenterology and Hepatology, vol. 3, no. 6, pp. 404-412 . https://doi.org/10.1016/S2468-1253(18)30082-7
The Lancet Gastroenterology and Hepatology, 3(6), 404-412. Elsevier Ltd
lancet. Gastroenterology & hepatology, 3(6), 404-412. Elsevier Limitedمصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Population, Equivalence Trials as Topic, Inflammatory bowel disease, 03 medical and health sciences, 0302 clinical medicine, Crohn Disease, Gastrointestinal Agents, Internal medicine, medicine, Clinical endpoint, Humans, Prospective Studies, education, Adverse effect, Biosimilar Pharmaceuticals, Aged, Aged, 80 and over, education.field_of_study, Gastrointestinal agent, Hepatology, business.industry, Remission Induction, Gastroenterology, Antibodies, Monoclonal, Middle Aged, medicine.disease, Ulcerative colitis, Infliximab, Clinical trial, 030220 oncology & carcinogenesis, Colitis, Ulcerative, Female, 030211 gastroenterology & hepatology, business, medicine.drug
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0209cb20473cdf82550b9520d983331
https://doi.org/10.1016/s2468-1253(18)30082-7 -
3
المؤلفون: R. Bos, Yvonne J B van Megen, Joanne Bloemsaat, Petra Vos, Marc R. Kok, Gerard D’haens, Theo Rispens, Lindy-Anne Korswagen, Michael T. Nurmohamed
المصدر: Abstracts Accepted for Publication.
مصطلحات موضوعية: medicine.medical_specialty, education.field_of_study, Intention-to-treat analysis, business.industry, Population, Biosimilar, Phase IV Trial, Infliximab, Clinical trial, Tolerability, Quality of life, Internal medicine, medicine, business, education, medicine.drug
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::878f451c9a7e4c99d3c672e8cf1d7632
https://doi.org/10.1136/annrheumdis-2019-eular.7286 -
4
المؤلفون: W van de Vrie, Joanne Minekus, Geert R. D'Haens, Anne S. Strik, Yvonne J B van Megen, Theo Rispens
المصدر: Gastroenterology. 152:S66
مصطلحات موضوعية: 030213 general clinical medicine, medicine.medical_specialty, Crohn's disease, Hepatology, business.industry, Gastroenterology, Biosimilar, Serum concentration, medicine.disease, Infliximab, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, 030211 gastroenterology & hepatology, In patient, business, Prospective cohort study, medicine.drug
Full Text via ClinicalKey